<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" version="2.0">
  <channel>
    <title>Stockwatch - Key Events</title>
    <link>https://www.stockwatch.live/</link>
    <description>Real-time corporate announcements, deals, and financial results.</description>
    <lastBuildDate>Thu, 29 Jan 2026 01:42:06 +0000</lastBuildDate>
    <language>en-in</language>
    <atom:link href="https://api.stockwatch.live/api/keyEvents" rel="self" type="application/rss+xml" />
    
    <item>
      <title>[PPLPHARMA] Piramal Pharma Reports Q3 and Nine Months Results for 2025 with Rs. 26.94 Crores Incremental Impact from New Labour Codes</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=Piramal+Pharma+Ltd&title=Piramal+Pharma+Reports+Q3+and+Nine+Months+Results+for+2025+with+Rs.+26.94+Crores+Incremental+Impact+from+New+Labour+Codes&newsId=a7d61427-133e-4695-8011-c9d9614df0dd&token=YTdkNjE0MjctMTMz</link>
      <guid isPermaLink="false">a7d61427-133e-4695-8011-c9d9614df0dd</guid>
      <pubDate>Thu, 29 Jan 2026 00:10:29 +0000</pubDate>
      <category>Quarterly Result</category>
      <description><![CDATA[<p>Piramal Pharma Ltd. has reported its unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The company&apos;s total expenses for the nine-month period stood at Rs. 2,515.06 crores, with a net profit of Rs. 406.20 crores. The company operates in one segment, and the financial results have been prepared in accordance with the Indian Accounting Standards. The Government of India&apos;s new Labour Codes has resulted in an incremental impact of Rs. 26.94 crores, which has been presented under &apos;Exceptional Items&apos; in the financial results. The company will continue to monitor the finalization of Central/State Rules and provide appropriate accounting effects as needed.</p><ul><li>Unaudited standalone financial results for Q3 and nine months ended December 31, 2025.</li><li>Total expenses for the nine-month period stood at Rs. 2,515.06 crores.</li><li>Net profit of Rs. 406.20 crores for the nine-month period.</li><li>Incremental impact of Rs. 26.94 crores due to new Labour Codes.</li><li>Company operates in one segment and financial results prepared in accordance with Indian Accounting Standards.</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/2871069a-9572-48d6-8443-199dd3b96fe8.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: Piramal Pharma Ltd | Category: Quarterly Result</small>]]></description>
    </item>
    <item>
      <title>[NSDL] National Securities Depository Ltd Reports 15.4% YoY Growth in Total Income for Q3FY26</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=National+Securities+Depository+Ltd&title=National+Securities+Depository+Ltd+Reports+15.4%25+YoY+Growth+in+Total+Income+for+Q3FY26&newsId=eb746d5a-c125-42b8-a823-64d4b69f15f6&token=ZWI3NDZkNWEtYzEy</link>
      <guid isPermaLink="false">eb746d5a-c125-42b8-a823-64d4b69f15f6</guid>
      <pubDate>Thu, 29 Jan 2026 00:01:40 +0000</pubDate>
      <category>Quarterly Result</category>
      <description><![CDATA[<strong>ðŸ”¥ Trending</strong><br/><p>National Securities Depository Ltd (NSDL) has announced its unaudited consolidated and standalone financial results for the quarter ended December 31, 2025. The total income for the quarter increased by 15.4% YoY to Rs. 198.7 crore. The net profit after tax grew marginally by 0.5% YoY to Rs. 77.9 crore. The company&apos;s net Beneficiary Owner (BO) market share increased significantly to 15.89% in 9M FY 26 from 8.84% in 9M FY 2025. NSDL has added 13 lakhs net BO accounts for Q3 FY26 and has a market share of 86.2% by total demat custody value as of December 2025. The company has implemented the provisions of the new labour law, i.e., the Code on Social Security, 2020, and has recognized its impact on standalone and consolidated basis during Q3 FY26. Protean eGov Technologies Ltd. has acquired a 4.95% stake in NSDL Payments Bank Ltd. for Rs. 30.2 crore.</p><ul><li>Total income increased by 15.4% YoY to Rs. 198.7 crore</li><li>Net profit after tax grew marginally by 0.5% YoY to Rs. 77.9 crore</li><li>Net BO market share increased significantly to 15.89% in 9M FY 26</li><li>Added 13 lakhs net BO accounts for Q3 FY26</li><li>Market share of 86.2% by total demat custody value as of December 2025</li><li>Protean eGov Technologies Ltd. acquired a 4.95% stake in NSDL Payments Bank Ltd. for Rs. 30.2 crore</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/1b37f0d4-1f9e-452f-a208-35221bb48b68.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: National Securities Depository Ltd | Category: Quarterly Result</small>]]></description>
    </item>
    <item>
      <title>[PPLPHARMA] Piramal Pharma Limited Announces Q3 and 9M FY26 Results with Revenue from Operations at â‚¹ 2,140 Crores and â‚¹ 6,117 Crores respectively</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=Piramal+Pharma+Ltd&title=Piramal+Pharma+Limited+Announces+Q3+and+9M+FY26+Results+with+Revenue+from+Operations+at+%E2%82%B9+2%2C140+Crores+and+%E2%82%B9+6%2C117+Crores+respectively&newsId=201d3423-79ee-4c92-b2dd-20a9baa332c6&token=MjAxZDM0MjMtNzll</link>
      <guid isPermaLink="false">201d3423-79ee-4c92-b2dd-20a9baa332c6</guid>
      <pubDate>Thu, 29 Jan 2026 00:01:31 +0000</pubDate>
      <category>Quarterly Result</category>
      <description><![CDATA[<strong>ðŸ”¥ Trending</strong><br/><p>Piramal Pharma Limited, a leading global pharmaceutical, health and wellness company, announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31Â° December 2025. The company reported a revenue from operations of â‚¹ 2,140 Crores for Q3FY26 and â‚¹ 6,117 Crores for 9MFY26. The CDMO segment reported a revenue of â‚¹ 1,166 Crores for Q3FY26 and â‚¹ 3,207 Crores for 9MFY26. The CHG segment reported a revenue of â‚¹ 668 Crores for Q3FY26 and â‚¹ 1,948 Crores for 9MFY26. The PCH segment reported a revenue of â‚¹ 334 Crores for Q3FY26 and â‚¹ 954 Crores for 9MFY26. The company also announced the acquisition of KenalogÂ®, a branded commercial injectable product with complex manufacturing requirements, from Bristol-Myers Squibb.</p><ul><li>Revenue from Operations for Q3FY26 at â‚¹ 2,140 Crores and â‚¹ 6,117 Crores for 9MFY26.</li><li>CDMO segment reported a revenue of â‚¹ 1,166 Crores for Q3FY26 and â‚¹ 3,207 Crores for 9MFY26.</li><li>CHG segment reported a revenue of â‚¹ 668 Crores for Q3FY26 and â‚¹ 1,948 Crores for 9MFY26.</li><li>PCH segment reported a revenue of â‚¹ 334 Crores for Q3FY26 and â‚¹ 954 Crores for 9MFY26.</li><li>Acquisition of KenalogÂ®, a branded commercial injectable product with complex manufacturing requirements, from Bristol-Myers Squibb.</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/00c6eb45-3d4f-4c58-86e9-69ee9f3ecd2b.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: Piramal Pharma Ltd | Category: Quarterly Result</small>]]></description>
    </item>
    <item>
      <title>[GMPL] G M Polyplast Ltd Board Meeting Scheduled for 09/02/2026</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=G+M+Polyplast+Ltd&title=G+M+Polyplast+Ltd+Board+Meeting+Scheduled+for+09%2F02%2F2026&newsId=de91d9c4-4b8b-4c7f-b5c9-e781adaf956f&token=ZGU5MWQ5YzQtNGI4</link>
      <guid isPermaLink="false">de91d9c4-4b8b-4c7f-b5c9-e781adaf956f</guid>
      <pubDate>Thu, 29 Jan 2026 00:01:19 +0000</pubDate>
      <category>Board Meeting</category>
      <description><![CDATA[<p>G M Polyplast Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2026. The meeting will be held at 03:00 P.M. and will consider business(es) other than those specified under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Company Secretary &amp; Compliance Officer, Dimple Pariyar, has confirmed the meeting.</p><ul><li>G M Polyplast Ltd Board Meeting Scheduled for 09/02/2026</li><li>The meeting will consider business(es) other than those specified under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</li><li>The meeting will be held at 03:00 P.M.</li><li>Dimple Pariyar, the Company Secretary &amp; Compliance Officer, has confirmed the meeting</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/00f0f9f4-6080-4e4b-91f9-4373e1501041.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: G M Polyplast Ltd | Category: Board Meeting</small>]]></description>
    </item>
    <item>
      <title>[PPLPHARMA] Piramal Pharma Ltd. Announces Q3 and 9M Unaudited Financial Results for 2025</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=Piramal+Pharma+Ltd&title=Piramal+Pharma+Ltd.+Announces+Q3+and+9M+Unaudited+Financial+Results+for+2025&newsId=37b29404-a82c-43ff-b05f-d47686b913b3&token=MzdiMjk0MDQtYTgy</link>
      <guid isPermaLink="false">37b29404-a82c-43ff-b05f-d47686b913b3</guid>
      <pubDate>Wed, 28 Jan 2026 20:32:36 +0000</pubDate>
      <category>Quarterly Result</category>
      <description><![CDATA[<p>Piramal Pharma Ltd. has announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The company&apos;s total expenses for the quarter were Rs. 347.06 crores, and for the nine months ended December 31, 2025, the total expenses were Rs. 1,107.77 crores. The company&apos;s earnings per equity share (EPS) for the quarter and nine months ended December 31, 2025, were not provided in the announcement. The company&apos;s total comprehensive income for the period was Rs. 696.90 crores. The company operates in only one segment, and the unaudited standalone financial results have been prepared in accordance with the Indian Accounting Standards as prescribed under section 133 of the Companies Act, 2013.</p><ul><li>Piramal Pharma Ltd. announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025.</li><li>Total expenses for the quarter were Rs. 347.06 crores, and for the nine months ended December 31, 2025, the total expenses were Rs. 1,107.77 crores.</li><li>The company&apos;s earnings per equity share (EPS) for the quarter and nine months ended December 31, 2025, were not provided in the announcement.</li><li>The company&apos;s total comprehensive income for the period was Rs. 696.90 crores.</li><li>The unaudited standalone financial results have been prepared in accordance with the Indian Accounting Standards as prescribed under section 133 of the Companies Act, 2013.</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/fd285e0c-f6c7-4b38-af17-bf9df92c06a4.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: Piramal Pharma Ltd | Category: Quarterly Result</small>]]></description>
    </item>
    <item>
      <title>[NDTV] New Delhi Television Ltd Reports Utilization of Rights Issue Proceeds for Q4 2025</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=NEW+DELHI+TELEVISION+LTD.&title=New+Delhi+Television+Ltd+Reports+Utilization+of+Rights+Issue+Proceeds+for+Q4+2025&newsId=c349cffb-20b9-489d-8859-8f6d1229f5b4&token=YzM0OWNmZmItMjBi</link>
      <guid isPermaLink="false">c349cffb-20b9-489d-8859-8f6d1229f5b4</guid>
      <pubDate>Wed, 28 Jan 2026 20:32:24 +0000</pubDate>
      <category>Quarterly Result</category>
      <description><![CDATA[<p>New Delhi Television Ltd, a TV Broadcasting and Software Production company, has utilized the proceeds from its Rights Issue of Rs. 396.50 crore as per the objects of the issue. The company has spent Rs. 71.00 crore on strategic initiatives, Rs. 229.00 crore on repayment of borrowings, and Rs. 94.31 crore on general corporate purposes. The remaining Rs. 2.19 crore, originally allocated for issue expenses, has been reallocated towards general corporate purposes. The utilization of funds is in line with the offer document and has been verified by the statutory auditor, S N Dhawan &amp; Co LLP.</p><ul><li>New Delhi Television Ltd has utilized the proceeds from its Rights Issue as per the objects of the issue.</li><li>Rs. 71.00 crore has been spent on strategic initiatives, Rs. 229.00 crore on repayment of borrowings, and Rs. 94.31 crore on general corporate purposes.</li><li>The remaining Rs. 2.19 crore, originally allocated for issue expenses, has been reallocated towards general corporate purposes.</li><li>The utilization of funds is in line with the offer document.</li><li>The utilization of funds has been verified by the statutory auditor, S N Dhawan &amp; Co LLP.</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/6ae1164b-e838-4a9a-80ee-b53a592f1bea.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: NEW DELHI TELEVISION LTD. | Category: Quarterly Result</small>]]></description>
    </item>
    <item>
      <title>[SURAJEST] Suraj Estate Developers Delivers Highest-Ever Q3 &amp; 9MFY26 Operational Performance, Backed by Commercial Launch</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=Suraj+Estate+Developers+Ltd&title=Suraj+Estate+Developers+Delivers+Highest-Ever+Q3+%26+9MFY26+Operational+Performance%2C+Backed+by+Commercial+Launch&newsId=e55569cf-c872-4be5-a008-8a3cf66449f9&token=ZTU1NTY5Y2YtYzg3</link>
      <guid isPermaLink="false">e55569cf-c872-4be5-a008-8a3cf66449f9</guid>
      <pubDate>Wed, 28 Jan 2026 20:32:10 +0000</pubDate>
      <category>New Launch</category>
      <description><![CDATA[<strong>ðŸ”¥ Trending</strong><br/><p>Suraj Estate Developers Limited, a leading real estate player focused on the South-Central Mumbai (SCM) market, announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a significant increase in sales value, sales area, and collections for Q3FY26 and 9MFY26. The company also launched a new commercial project, Suraj One Business Bay, and acquired land parcels in Bandra West. These developments reflect sustained demand in the SCM market and reinforce the commercial segment as a key growth driver.</p><ul><li>Q3FY26 sales value increased by 137% y-o-y to Rs 253 Crores</li><li>Q3FY26 sales area increased by 211% y-o-y to 51,826 Sq ft</li><li>Q3FY26 collections increased by 48% y-o-y to Rs 124 Crores</li><li>Launched Suraj One Business Bay and achieved ~40,000 sq. ft. of sales within 45 days</li><li>Acquired two land parcels in Bandra West to enhance scale for residential project launches</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/202e8b6b-10f2-4b19-bff4-c0e99a528848.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: Suraj Estate Developers Ltd | Category: New Launch</small>]]></description>
    </item>
    <item>
      <title>[GAYATRI] Gayatri Sugars Granted Trading Approval for 13,26,664 Equity Shares</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=GAYATRI+SUGARS+LTD.&title=Gayatri+Sugars+Granted+Trading+Approval+for+13%2C26%2C664+Equity+Shares&newsId=29e6cdab-9a6e-413c-9672-e504e1a6b6c9&token=MjllNmNkYWItOWE2</link>
      <guid isPermaLink="false">29e6cdab-9a6e-413c-9672-e504e1a6b6c9</guid>
      <pubDate>Wed, 28 Jan 2026 20:31:38 +0000</pubDate>
      <category>New Launch</category>
      <description><![CDATA[<p>Gayatri Sugars Ltd has received trading approval for 13,26,664 Equity Shares of Rs. 10/- each issued to Non-Promoters on a preferential basis pursuant to conversion of warrants. The approval was granted by BSE Limited on January 27, 2026. The shares, bearing distinctive numbers from 66200302 to 67526965, will be listed on the Exchange effective from January 28, 2026.</p><ul><li>Gayatri Sugars receives trading approval for 13,26,664 Equity Shares</li><li>Shares issued to Non-Promoters on a preferential basis pursuant to conversion of warrants</li><li>Shares listed on BSE Limited</li><li>Shares bear distinctive numbers from 66200302 to 67526965</li><li>Effective from January 28, 2026</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/8f3e960b-8669-4c97-9f05-8515b05eacef.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: GAYATRI SUGARS LTD. | Category: New Launch</small>]]></description>
    </item>
    <item>
      <title>[HGINFRA] H.G. Infra Engineering Chairman Granted Interim Protection by Court</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=H.G.+Infra+Engineering+Ltd&title=H.G.+Infra+Engineering+Chairman+Granted+Interim+Protection+by+Court&newsId=568c8f4a-2bc4-436a-82e6-9628b00ae5b4&token=NTY4YzhmNGEtMmJj</link>
      <guid isPermaLink="false">568c8f4a-2bc4-436a-82e6-9628b00ae5b4</guid>
      <pubDate>Wed, 28 Jan 2026 20:31:34 +0000</pubDate>
      <category>Legal</category>
      <description><![CDATA[<p>H.G. Infra Engineering Ltd. announced that its Chairman and Managing Director, Mr. Harendra Singh, has been granted interim protection with no coercive steps by the Court of Spl. Judge, CBI-1, Patna. The order was given on January 27, 2026, and the certified copy was received on January 28, 2026. The company clarified that a copy of the FIR has not been formally served by the Central Bureau of Investigation (CBI), but based on the information available on the CBIâ€™s official website, Mr. Harendra Singh has been named as a party in the FIR. The company and its officials have cooperated with the CBI and will continue to provide any clarification or information as required. The company&apos;s business is conducted in the normal course, and it remains committed to high standards of corporate governance and transparency. Any further developments will be promptly intimated to the Stock Exchanges.</p><ul><li>H.G. Infra Engineering Chairman, Mr. Harendra Singh, granted interim protection by the Court</li><li>Company continues to cooperate with the Central Bureau of Investigation (CBI)</li><li>Company&apos;s business operates as usual</li><li>Commitment to high standards of corporate governance and transparency</li><li>Further developments to be promptly informed to Stock Exchanges</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/d223910e-6fc4-47a9-b2e4-36348b0a9a91.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: H.G. Infra Engineering Ltd | Category: Legal</small>]]></description>
    </item>
    <item>
      <title>[PANAENERG] Panasonic Energy India Board Meeting Postponed: Unaudited Financial Results for Q3 and Nine Months Ended December 31, 2025 Not Approved</title>
      <link>https://www.stockwatch.live/news?showModal=true&name=PANASONIC+ENERGY+INDIA+COMPANY+LTD.-%24&title=Panasonic+Energy+India+Board+Meeting+Postponed%3A+Unaudited+Financial+Results+for+Q3+and+Nine+Months+Ended+December+31%2C+2025+Not+Approved&newsId=09755f5d-4cbb-4d09-8b54-d5c027a348fd&token=MDk3NTVmNWQtNGNi</link>
      <guid isPermaLink="false">09755f5d-4cbb-4d09-8b54-d5c027a348fd</guid>
      <pubDate>Wed, 28 Jan 2026 20:31:30 +0000</pubDate>
      <category>Board Meeting</category>
      <description><![CDATA[<p>The Board Meeting of Panasonic Energy India Company Ltd., originally scheduled for January 29, 2026, to approve the unaudited financial results for the quarter and nine months ended December 31, 2025, has been cancelled due to unavoidable circumstances. A new date for the Board Meeting will be announced and shared with the Stock Exchange(s) as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The updated information is also available on the company&apos;s website.</p><ul><li>Panasonic Energy India Board Meeting postponed</li><li>Unaudited financial results for Q3 and nine months ended December 31, 2025 not approved</li><li>New date for the Board Meeting to be announced</li><li>Information to be shared with Stock Exchange(s) as required</li><li>Updated information available on the company&apos;s website</li></ul><p>ðŸ“„ <a href="https://www.bseindia.com/xml-data/corpfiling/AttachLive/03735b2d-19fe-4517-9136-0602ff67da26.pdf">Read Official Filing (PDF)</a></p><br/><small>Company: PANASONIC ENERGY INDIA COMPANY LTD.-$ | Category: Board Meeting</small>]]></description>
    </item>
  </channel>
</rss>